 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...174175176177178179180181182183184...208209» |
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment closed, Trial completion date, Trial primary completion date: PUMCH-NPLA81H-Ahead-T302: Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - May 7, 2020
P3, N=118, Active, not recruiting, Sponsor: Peking Union Medical College Hospital
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Nov 2019 --> Jul 2020
- || Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Trial completion, Trial completion date: Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects (clinicaltrials.gov) - May 7, 2020
P1, N=6, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Nov 2019 --> Jul 2020 Recruiting --> Completed | Trial completion date: Oct 2019 --> Jun 2019
- ||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial initiation date: Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - May 7, 2020
P3, N=762, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed | Trial completion date: Oct 2019 --> Jun 2019 Initiation date: Feb 2020 --> Jun 2020
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New trial: A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer (clinicaltrials.gov) - May 7, 2020
P, N=40, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- | cyclosporine / Generic mfg., perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
Journal: Perfluorohexyloctane (FH) as a delivery agent for cyclosporine A in dry eye syndrome therapy - Langmuir monolayer study complemented with infrared nanospectroscopy. (Pubmed Central) - May 7, 2020
We have highlighted that FH increases the availability of CsA and therefore is appropriate carrier for CsA topical delivery to the eye in the dry eye syndrome. In addition, the applied herein procedure provides a simple, low-cost laboratory tool for preliminary studies involving membrane active pharmaceuticals, preceding in vivo tests.
- | dexmedetomidine nasal spray / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children (clinicaltrials.gov) - May 6, 2020
P1, N=48, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
In addition, the applied herein procedure provides a simple, low-cost laboratory tool for preliminary studies involving membrane active pharmaceuticals, preceding in vivo tests. Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Jun 2020 --> Aug 2020
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor. (Pubmed Central) - May 6, 2020
The changing number of CD4+CD25+ T cells may be a good indicator for apatinib prognosis. Natural killer cells and T cells subgroup did not change much after apatinib, and they were not independent prognostic factors for progression-free survival.
- |||| Itari (linperlisib) / Shanghai YingLi Pharma
New P2 trial: A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov) - May 6, 2020
P2, N=140, Not yet recruiting, Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: LungMate-003: Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - May 6, 2020
P2, N=99, Not yet recruiting, Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
New P3 trial, New P4 trial, Minimal residual disease: Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL (clinicaltrials.gov) - May 4, 2020
P4, N=28, Recruiting, Sponsor: Zhongda Hospital
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Efficacy and safety of transarterial chemoembolization (TACE) plus apatinib as compared with TACE alone for recurrent hepatocellular carcinoma: A prospective randomized controlled trial () - May 3, 2020 - Abstract #ESMOGI2020ESMO_GI_30;
Legal entity responsible for the study The authors. Funding This work was supported by grants from the Scientific and Technological Innovation Projects of Chongqing (cstc2017shmsA00011, cstc2017shmsA10005 and cstc2018jscx-mszdX0012).
- | AiTan (rivoceranib) / HLB Bio Group
Retrospective data, Journal: Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: a retrospective, multicenter study. (Pubmed Central) - May 2, 2020
Funding This work was supported by grants from the Scientific and Technological Innovation Projects of Chongqing (cstc2017shmsA00011, cstc2017shmsA10005 and cstc2018jscx-mszdX0012). Apatinib showed promising therapeutic effects on advanced HCC with lung metastasis, highlighting a population that could benefit preferentially from this treatment.
- | AiTan (rivoceranib) / HLB Bio Group
Journal, IO Biomarker: Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway. (Pubmed Central) - May 2, 2020
Apatinib showed promising therapeutic effects on advanced HCC with lung metastasis, highlighting a population that could benefit preferentially from this treatment. The experiment proves that Apatinib can effectively suppress the proliferation and induce the apoptosis of human gastric cancer HGC-27 cells, the mechanism of which is related to the inhibition on phosphorylation of the PI3K/Akt signaling pathway.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
Clinical, Journal, Combination therapy: Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib. (Pubmed Central) - May 1, 2020
The experiment proves that Apatinib can effectively suppress the proliferation and induce the apoptosis of human gastric cancer HGC-27 cells, the mechanism of which is related to the inhibition on phosphorylation of the PI3K/Akt signaling pathway. No abstract available
- ||| retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Enrollment open: SHR-1701-I-101: SHR-1701 in Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov) - May 1, 2020
P1, N=112, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
No abstract available Not yet recruiting --> Recruiting
- |||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Enrollment change, Trial completion date: A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy (clinicaltrials.gov) - Apr 30, 2020
P3, N=885, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=568 --> 885 | Trial completion date: Jul 2022 --> Mar 2023
- ||| retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Enrollment open, Trial completion date, Trial primary completion date: SHR-1701-I-102: SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov) - Apr 30, 2020
P1, N=238, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | N=568 --> 885 | Trial completion date: Jul 2022 --> Mar 2023 Not yet recruiting --> Recruiting | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2020 --> Jul 2021
- ||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Apr 29, 2020
P2, N=67, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2020 --> Jul 2021 Recruiting --> Active, not recruiting | N=110 --> 67 | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- AiTan (rivoceranib) / HLB Bio Group, temozolomide / Generic mfg.
[VIRTUAL] Phase II study of apatinib combined with temozolomide in advanced melanoma patients after failure of anti-PD-1 therapy. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5732;
In pts progressed after anti-PD-1 therapy, apatinib in combination with temozolomide demonstrated promising efficacy and favorable safety profile. Research Funding: CSCO-Hengrui Oncology Research Fund
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Efficacy and safety of apatinib in patients with recurrent or refractory melanoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5715;
P2
The toxicity was manageable. Research Funding: None
- AiTan (rivoceranib) / HLB Bio Group, docetaxel / Generic mfg.
[VIRTUAL] Efficacy and safety of apatinib plus docetaxel for non-squamous non-small cell lung cancer with bone metastases. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5684;
The therapeutic regime may be an option for NSCLC with bone metastases. Research Funding: None
- AiTan (rivoceranib) / HLB Bio Group, pemetrexed / Generic mfg.
[VIRTUAL] Apatinib combined with pemetrexed-platinum doublet chemotherapy for chemo-naïve Chinese non-squamous non-small cell lung cancer patients: A prospective phase II clinical study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5678;
- paclitaxel / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Anti-PD-1 antibody monotherapy or anti-PD-1 antibody combination with chemotherapy treated non-small cell lung cancer (NSCLC) patients with EGFR mutation: A retrospective analysis. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5634;
Anti-PD-1 antibody combined chemotherapy seems showed moderate effect on NSCLC patients with EGFR mutation who have received anti-EGFR therapy. Research Funding: the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent (QNRC2016646); the China Postdoctoral Science Foundation (2017M621680); the Six talent peaks project in Jiangsu Province (WSN-039)
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab in the treatment of patients with advanced lung cancer: A multicenter, prospective, cohort study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5593;
This Real-world research showed current treatment status of advanced lung cancer and provides preliminary evidence for camrelizumab treating with advanced lung cancer, and we expect follow-up data to provide more clues. Research Funding: None
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Efficacy and safety of SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous cell carcinoma: A phase II study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5530;
This treatment may be a promising method for advanced LUSC as a first-line treatment. Fund Project (No: 2017FC-CXYY-3007) & Project (No: 2017MBD-013).
- Herceptin (trastuzumab) / Roche
[VIRTUAL] Characterization of ERBB2 alterations in non-small cell lung cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5496;
P1, P2
One third of tumors with extracellular domain ERBB2 mutation had EGFR mutation. Tarloxitinib (NCT03805841), trastuzumab deruxtucan (NCT03505719), pyrotinib (NCT02500199), poziotinib (NCT03318939) are just a few of the novel ERBB2 inhibitors available in clinical trials.
- [VIRTUAL] Clinical management of lung adenocarcinoma patients with HER2 V659E mutation. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5464;
We revealed the prevalence of ERBB2 V659E in Chinese LUAD patients and elucidated the genomic profile of ERBB2 V659E mutant. This study paves avenue for the utilization of the novel HER2 inhibitors pyrotinib in ERBB2 V659E mutant LUAD patients.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] First-line apatinib plus chemotherapy in extensive-stage small-cell lung cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5429;
Our study suggests that oral apatinib plus chemotherapy should be considered an active and safe treatment in patients with first-line treatment of extensive-stage small-cell lung cancer. Research Funding: None
- TG-1701 / TG Therapeutics
[VIRTUAL] Safety and activity of the once daily selective Bruton tyrosine kinase (BTK) inhibitor TG-1701 in patients with chronic lymphocytic leukemia (CLL) and lymphoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5171;
- [VIRTUAL] A comparison of CD34+ mobilization effects of standard dose pegfilgrastim (Peg) versus low-dose peg combined with plinabulin (Plin). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5164;
We evaluated CD34+ cell counts and adverse events (AE) with low dose Peg combined with Plin vs full dose Peg. In a subset of Breast Cancer pts in the CIN Ph 2 trial BPI-2358-106 (NCT0329457) receiving TAC (taxotere (75), doxorubicin (50 ) and cyclophosphamide (500) mg/m2, pts also received either Peg 6mg (n = 7) or low dose peg ( n = 9, of which 7pts received 3mg and 2 pts 1.5 mg Peg) combined with Plin (20 mg/m2). Research Funding: BeyondSpring Pharmaceuticals Inc
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4164;
The combination of a TKI and anti-PD-1 antibody is feasible as a conversion therapy. Research Funding: None
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A phase II study of apatinib treatment for advanced biliary tract carcinoma after failure of the standard chemotherapy. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4158;
P2
For the patients with advanced biliary tract carcinoma, apatinib showed an anti-tumor activity with acceptable safety. Research Funding: None
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4084;
It is also noted that initially unresectable HCC may be converted to resectable HCC following this combination treatment. *, including 6 patients underwent R0 resection.
- [VIRTUAL] Hepatic artery infusion chemotherapy combined with apatinib and toripalimab in advanced hepatocellular carcinoma: Real-world data from a single center. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4076;
In patients with advanced HCC, treatment with strategically timed triple combination therapy of HAIC, apatinib, and toripalimab shows promising clinical benefit and safety. Research Funding: None
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Efficacy and safety of camrelizumab combined with FOLFOX as neoadjuvant therapy for patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4023;
Camrelizumab combined with FLOFOX as neoadjuvant treatment for patients with locally advanced GC/GEJC showed acceptable toxicity and promising efficacy with low complications and mortality. Research Funding: Jiangsu Hengrui Medicine Co., Ltd.
- irinotecan / Generic mfg., capecitabine / Generic mfg.
[VIRTUAL] Irinotecan with or without capecitabine as a beyond 2nd line regime for esophago-gastric adenocarcinomas. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4019;
Irinotecan in combination with capecitabine is efficacious as a beyond 2nd line regime in metastatic EG with an acceptable toxicity profile with a limited role in patients with resistant disease to first line platinum-based chemotherapies with fluoropyramidines. Research Funding: None
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] NIPASS: A prospective, phase II, single-arm study of neoadjuvant treatment with camrelizumab, apatinib, and S-1 (CAS) for resectable, locally advanced gastric cancer (LAGC). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4010;
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab (Camre) plus taxane-based chemotherapy (CT): Clinical outcomes and dynamic monitoring of CEA as a predictive biomarker of response in patients with recurrent or advanced esophageal squamous cell carcinoma (ESCC). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3998;
This combination regimen warrants further exploration in a prospective clinical trial. CEA dynamics may be a useful tool to monitor disease evolution in this setting.
- AiTan (rivoceranib) / HLB Bio Group, fluorouracil / Generic mfg.
[VIRTUAL] Predictive and prognostic factors of apatinib in metastatic colorectal cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3918;
NLR could be the independent prognostic factor of OS in mCRC. Additional studies are warranted for further validation.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] FLT1 amplification predicts poor response in metastatic colorectal cancer patients treated with apatinib as 3rd line treatment. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3859;
FLT1 encodes VEGFR1, which could compete with VEGFR2 for binding with VEGF, potentially explaining the inferior response to apatinib observed in pateints harboring FLT1 amplification. Larger cohorts are needed to validate the finding.
- pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
[VIRTUAL] Studies on the efficacy of pyrotinib in the treatment of HER-2 positive advanced solid tumors. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3787;
11 cases of trastuzumab were changed to anti-HER-2 after treatment failure, of which 2 cases were treated with pirotinib after trastuzumab and lapatinib failed treatment...The common symptoms were diarrhea (100%), hand and foot skin reaction (38%), rash (8%), etc. Grade 3 to 4 adverse events occurred in 1 patient (8%) received pyrotinib plus capecitabine...The treatment of HER-2 positive advanced solid tumors with pyrotinib have good exact affect, and the toxicity could be controlled. Research Funding: None
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Real-world observation of the efficacy and prognostic factors analysis of apatinib for patients with advanced gastric cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3656;
This study help us to identify patients who has potential benefit from apatinib. Research Funding: Nanjing Science and technology development projects (Grant No.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Efficacy and safety of apatinib combined with TACE in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3652;
Apatinib combined with TACE might be effective and tolerant in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Research Funding: None
- Keytruda (pembrolizumab) / Merck (MSD), AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Tumour immune characterization in adenoid cystic carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3566;
Our study highlights the immune infiltration patterns and unravels mRNA signatures with prognostic utility and immunotherapeutic biomarker potential in ACC. Research Funding: None
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab in advanced or metastatic solid tumor patients with microsatellite instability–high/mismatch repair-deficient: Results from an open-label exploratory study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3515;
The survival benefits will be further observed. Research Funding: None
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Retrospective analysis of immune checkpoint inhibitor-associated myocarditis from 12 cancer centers in China. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3505;
Regular monitoring of cardiac biomarkers and ECG is helpful for early diagnosis. Research Funding: None
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] A dedicated lung cancer immunotherapy outpatient clinic: The first experience in China. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3186;
Therapeutic alliance of IO clinics has already been established with primarily 15 hospitals participated in. The design process and standardized workflow components will be further expanded to other cancers or conditions.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib to prolong overall survival from recurrence to death in metastatic breast cancer: A single-center experience from east China. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2952;
The adverse reactions are common, so it is necessary to guard against the severe adverse reactions that lead to poor prognosis. Research Funding: None
- pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, capecitabine / Generic mfg.
[VIRTUAL] Pyrotinib combined with capecitabine as first-line therapy for HER2-positive metastatic breast cancer: A pooled analysis of three randomized controlled trials. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2884;
P1/2, P3
The pooled analysis demonstrated pyrotinib plus capecitabine was efficacious as first-line therapy in patients with HER2-positive relapsed or metastatic breast cancer, offering a potent treatment option for these patients. Research Funding: Jiangsu Hengrui Medicine Co., Ltd
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib for patients (pts) with advanced soft tissue sarcoma (STS) after chemotherapy: A prospective, open-label, single-arm, multicentered study. (Poster Board 441) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2575;
P2
Some of the pts had a long-time benefit from the treatment. Apatinib was safe and generally well tolerated.